What is the optimal management of hypertension in a patient on sacubitril/valsartan (Entresto) and metoprolol who continues to have elevated blood pressure?

Management of Uncontrolled Hypertension on Entresto and Metoprolol

Add a thiazide or thiazide-like diuretic (such as chlorthalidone or hydrochlorothiazide) as your next step, followed by spironolactone if blood pressure remains uncontrolled.

Stepwise Approach

Since this patient is already on sacubitril/valsartan (Entresto, which contains an ARB component) and a beta-blocker (metoprolol), you have two of the foundational antihypertensive drug classes covered. The logical next step follows established guideline-directed therapy:

First Addition: Thiazide/Thiazide-like Diuretic

• Add chlorthalidone 12.5-25 mg daily or hydrochlorothiazide 25-50 mg daily 1
• The 2020 ISH guidelines clearly outline this as the third-line agent after ARB/ACEI and beta-blocker therapy
• Thiazide-like diuretics (chlorthalidone, indapamide) are preferred over hydrochlorothiazide due to longer duration of action and superior cardiovascular outcomes
• This creates a triple-therapy regimen that addresses volume status, which is often undertreated in resistant hypertension

Second Addition: Mineralocorticoid Receptor Antagonist

If BP remains elevated after optimizing the diuretic dose:

• Add spironolactone 25-50 mg daily (or eplerenone 50-100 mg daily if not tolerated) 2, 1, 3
• The 2024 ESC guidelines specifically recommend spironolactone as first-line therapy for resistant hypertension 3
• The 2007 AHA statement supports aldosterone receptor antagonists in heart failure patients with hypertension, noting they improve outcomes in severe HF (NYHA class III/IV or LVEF <40%) 2

Critical monitoring requirement: Check serum potassium and renal function within 1 week of adding spironolactone, then periodically, as both Entresto and spironolactone increase hyperkalemia risk 4

Alternative Fourth-Line Options

If spironolactone is contraindicated or not tolerated 1, 3:

• Amiloride (potassium-sparing diuretic)
• Doxazosin (alpha-blocker)
• Eplerenone (if spironolactone causes gynecomastia)
• Clonidine (centrally-acting agent)

Important Considerations Before Adding Medications

Verify True Resistant Hypertension

1. Confirm medication adherence - This is the most common cause of apparent treatment resistance 1
2. Check home or ambulatory BP monitoring - Office readings ≥140/90 mmHg should correlate with home BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg 1
3. Assess for white coat hypertension - Measure BP in both arms; use the higher reading 1

Optimize Current Regimen

• Ensure Entresto is at target dose: Work up to 97/103 mg twice daily (maximum tolerated dose) 4
• Verify metoprolol dosing: Ensure adequate beta-blockade (metoprolol succinate 200 mg daily is typical maximum for BP control)
• Address volume status: Patients on Entresto may have residual volume overload requiring diuretic therapy 2

Screen for Secondary Hypertension

Given treatment resistance, evaluate for:

• Obstructive sleep apnea (especially if overweight/obese) 5
• Primary aldosteronism (check aldosterone-to-renin ratio)
• Renal artery stenosis (if sudden worsening or flash pulmonary edema) 5
• Medication/substance interference (NSAIDs, decongestants, excessive alcohol, licorice)

Target Blood Pressure

• Goal: <130/80 mmHg for most patients 1, 3
• For patients with heart failure: <130/80 mmHg, though the 2007 AHA statement suggests consideration of even lower targets (<120/80 mmHg) in select cases 2
• Individualize for elderly/frail patients based on tolerability 1
• Achieve target within 3 months of treatment adjustment 1

Common Pitfalls to Avoid

1. Don't add another ARB or ACE inhibitor - Entresto already contains valsartan (ARB component); dual RAS blockade increases risk of hypotension, hyperkalemia, and acute kidney injury 4

2. Avoid non-dihydropyridine calcium channel blockers (verapamil, diltiazem) in heart failure patients - These are contraindicated due to negative inotropic effects 2

3. Monitor for hypotension - Entresto can cause symptomatic hypotension, especially when adding additional antihypertensives 4. Correct volume depletion before intensifying therapy.

4. Watch renal function closely - Both Entresto and spironolactone can impair renal function; monitor serum creatinine and eGFR 4

5. Don't use ACE inhibitors - Contraindicated with Entresto; must wait 36 hours between switching 4

Entresto-Specific Considerations

Real-world evidence demonstrates that sacubitril/valsartan provides superior BP reduction compared to ARBs alone 6, 7, 8, 9. Studies show:

• Mean systolic BP reduction of 12-16 mmHg when switching from other ARBs 9, 10
• Particularly effective in patients with low plasma renin activity 6
• Additional benefits include reduction in uric acid levels and NT-proBNP 9, 11

However, if BP remains uncontrolled despite optimized Entresto dosing, the issue is likely inadequate multi-drug therapy rather than insufficient RAS blockade.

When to Refer

If BP remains uncontrolled after adding both a diuretic and spironolactone (4-drug regimen), refer to a hypertension specialist for evaluation of secondary causes and consideration of additional interventions 1, 3.